-The Telegraph New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions. The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not...

-Economic and Political Weekly Since independence, India's national health policies have been aspirational but the end results have been limited. The National Health Policy 2015, which is in the process of being finalised, should, in place of the earlier "broadband" approach, adopt a "narrow focus" on primary healthcare through the National Rural Health Mission. The latter has focused on primary healthcare and has shown visible results. A slew of suggestions as...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...